

REMARKS UNDER 37 CFR § 1.111

Formal Matters

Claims 57-80 are pending after entry of the amendment above.

Claims 37-56 are canceled without prejudice to renewal.

Support for new claims 57-80 is found throughout the specification, and particularly at, for example: page 8, lines 8-10; page 11, line 22 to page 12, line 3; page 17, lines 27-28; page 36, lines 8-14; and page 39, lines 8-9.

Attached hereto is a marked-up version of the changes made to the specification. The attached page is captioned "Version with markings to show changes made."

Applicants respectfully request entry of the amendment.

No new matter has been added.

Response to Restriction Requirement

Applicants hereby elect the invention of Groups XVII-XXIII, drawn to methods of producing a polypeptide, which election is with traverse.

The election is not traversed with respect to the divisional of the claims to isolated polypeptides, methods of producing polypeptides, antibody, methods of producing antibody, method for determining altered TRRE activity, determining altered expression of TRRE activity, decreasing signal transduction, and methods for screening polynucleotides. Nevertheless, it is respectfully pointed out that this type of restriction is improper in a PCT National Stage application filed under 35 USC § 371.

The rejection is traversed to the extent the restriction of the claims is based on sequence identification number (SEQ. ID NO). Each of the claimed sequences have already been searched in the examination of pending application USSN 09/081,385. Accordingly, it would not be a burden on the Examiner to consider these claims together, and no restriction is permitted (MPEP § 804).

In the event that this restriction is maintained, applicants hereby provisionally elect SEQ. ID NO:9 for examination on the merits of the subject matter of the Group elected above. Applicants hereby request rejoinder of the other SEQ. ID NOs. into the application upon determination that SEQ. ID NO:9 is free of prior art.


Conclusion

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number IRVN-007CIP2.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 17, 2002

By:


Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

F:\DOCUMENT\IRVN (UC Irvine)\007cip2\Resp Rest Reqmt IRVN-007CIP2.doc

“Version with markings to show changes made.”

In the title:

Please replace the title on page 1, line 1, with the following rewritten title:

~~Factors Affecting Tumor Necrosis Factor Receptor Releasing Enzyme Activity~~
METHOD FOR PRODUCING TNF RECEPTOR RELEASING ENZYME

In the Claims

Cancel claims 37-56 without prejudice.

New claims 57-80 are added.